Price
No data yet.
Social Signal Score
Analyst Ratings
14 analystsRevenue
$67.58M+2100.69%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Miguel Martin
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 1,028
- Beta
- 1.45
- Country
- CA
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -11.61
Financials
Revenue
$67.58M+2100.7%Net Income
$-4.03MEBITDA
$-43.49MFree Cash Flow
$-9.86MEPS (diluted)
$-0.07Shares Outstanding (diluted)
61.68M+3931.1%Operating Expenses
$43.43MCash & Debt
$149.18MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $320.59M | $-121.76M | $-2.15 |
| 2025 | $343.29M | $1.59M | $0.03 |
| 2024 | $270.28M | $-69.33M | $-1.28 |
| 2023 | $223.80M | $-816.63M | $-8.17 |
| 2022 | $221.34M | $-1.74B | $-79.92 |
| 2021 | $245.25M | $-693.63M | $-40.92 |
| 2020 | $268.70M | $-3.28B | $-333.92 |
| 2019 | $245.54M | $-293.51M | $-36.65 |
| 2018 | $55.20M | $71.94M | $18.00 |
| 2017 | $18.07M | $-12.97M | $-5.58 |
| 2016 | $1.44M | $-5.72M | $-5.32 |
| 2015 | $0.00 | $-9.52M | $-9.87 |
| 2014 | $0.00 | $-399.7K | $-16.26 |
| 2013 | $0.00 | $-393.5K | $-0.29 |
Valuation
ACBhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100-20.00%Social Signal Score
Mentions (3)
- News247wallst.com·25d ago·Neutral
$250,000 in These 3 High-Income ETFs Could Pay You ~$2,800 a Month Options-income ETFs now offer monthly payouts that dwarf what traditional dividend stocks provide, but before you move a dollar, there are tax mechanics and capital preservation risks that most income investors completely overlook.
View source ↗ - Newscnbc.com·52d ago·Neutral
Marijuana reform is emerging as a midterm elections issue on both sides of the aisle With November's pivotal midterm elections fast approaching, cannabis reform is emerging as an issue. Two states, Massachusetts and Idaho, will vote on ballot initiatives regarding legalization, and in several others, including Kansas and Iowa, gubernatorial candidates are debating cannabis matters.
View source ↗ - Newszacks.com·55d ago·Positive
Should You Buy ACB Stock Amid Curaleaf's Hostile Takeover Attempt? Aurora Cannabis faces a potential Curaleaf takeover at a 45% premium, but investors must weigh the offer against ACB's standalone prospects.
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $-0.03 per share
Typical surprise -263.3% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$-0.05 vs $-0.13beat
- Thu, Jun 11$-0.71 vs $-0.07miss
- Wed, Feb 4$0.02 vs $0.10miss
- Wed, Nov 5$-0.65 vs $0.03miss
- Wed, Aug 6$-0.19 vs $0.18miss
- Wed, Jun 18$-0.24 vs $0.11miss
Estimates and results for ACB via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
- John Yarmuthhouse · KY03 · disclosed Feb 19, 2021 (7d later)Buy$1,001 - $15,000
- John Yarmuthhouse · KY03 · disclosed Nov 15, 2020 (10d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.